Serum Tumor Markers in Pancreatic Cancer—Recent Discoveries
Open Access
- 2 June 2010
- Vol. 2 (2), 1107-1124
- https://doi.org/10.3390/cancers2021107
Abstract
The low prevalence of pancreatic cancer remains an obstacle to the development of effective screening tools in an asymptomatic population. However, development of effective serologic markers still offers the potential for improvement of diagnostic capabilities, especially for subpopulations of patients with high risk for pancreatic cancer. The accurate identification of patients with pancreatic cancer and the exclusion of disease in those with benign disorders remain important goals. While clinical experience largely dismissed many candidate markers as useful markers of pancreatic cancer, CA19-9 continues to show promise. The present review highlights the development and the properties of different tumor markers in pancreatic cancer and their impact on the diagnostic and treatment of this aggressive disease.Keywords
This publication has 92 references indexed in Scilit:
- Inhibition of Hedgehog Signaling Enhances Delivery of Chemotherapy in a Mouse Model of Pancreatic CancerScience, 2009
- A Compendium of Potential Biomarkers of Pancreatic CancerPLoS Medicine, 2009
- Activation of Wnt signalling in stroma from pancreatic cancer identified by gene expression profilingJournal of Cellular and Molecular Medicine, 2008
- Co-expression of KLK6 and KLK10 as prognostic factors for survival in pancreatic ductal adenocarcinomaBritish Journal of Cancer, 2008
- Glycobiology in the cytosol: The bitter side of a sweet worldBiochimica et Biophysica Acta (BBA) - General Subjects, 2008
- Cancer Statistics, 2008CA: A Cancer Journal for Clinicians, 2008
- Systematic review of carbohydrate antigen (CA 19-9) as a biochemical marker in the diagnosis of pancreatic cancerEuropean Journal of Surgical Oncology, 2007
- The clinical value of serum CEA, CA19-9, and CA242 in the diagnosis and prognosis of pancreatic cancerEuropean Journal of Surgical Oncology, 2005
- Clinical relevance of serological markers in the detection and follow-up of pancreatic adenocarcinomaSurgical Oncology, 1996
- Tumour-associated trypsin inhibitor in the diagnosis of pancreatic carcinomaZeitschrift für Krebsforschung und Klinische Onkologie, 1994